Models for profiling the potential QT prolongation risk of drugs.

The appearance of QT prolongation and arrhythmic events associated with a compound undergoing clinical trials can greatly hamper drug development programs. Assessing the risk of a compound during preclinical studies to cause this cardiotoxicity is thus critically important to the pharmaceutical industry. A wide variety of preclinical approaches exist to evaluate potential QT issues, including in vitro, in vivo and in silico (i.